Quality Control and Compliant Production of Chromosomal STR Genotyping Kits: Practical Key Points from R&D to Registration

Key Quality Attributes and Validation Strategies

For the chromosome (13/18/21/X/Y) multiplex STR genotyping kit, its key quality attributes include specificity, sensitivity, precision, repeatability, stability, and interference resistance. Specificity validation should use reference samples with known genotypes (including normal diploid, trisomy, and sex chromosome abnormality samples) to evaluate whether the kit amplifies only the target STR loci without cross-reactivity. At the same time, the impact of common interfering substances (such as hemoglobin, heparin, ethanol, etc.) on PCR amplification needs to be tested to ensure the accuracy of detection results in general clinical sample matrices.

Sensitivity validation needs to determine the minimum DNA amount or minimum cell number detectable by the kit and evaluate its ability to detect low-proportion mosaicism (such as 20% trisomic cells). Typically, mosaic models are constructed by gradient dilution of mixtures of normal and abnormal samples, with repeated testing multiple times to determine the limit of detection. Precision includes intra-batch precision and inter-batch precision. The same sample should be tested multiple times using kits from the same batch and different batches, and the consistency of allele peak height ratios or genotype determination results should be statistically analyzed. Stability validation covers the performance of the kit under different storage temperatures (such as 2-8°C, -20°C) and different freeze-thaw cycles. Accelerated stability testing can provide a reference basis for real-time stability validation. All validation items should be designed according to international standards or industry guidelines (such as relevant CLSI documents), and complete raw data should be retained.

Key Points of Quality Control in the Production Process

In the production process, quality control involves three stages: raw materials, intermediate products, and finished products. Raw material quality control is the key starting point, including primer purity and sequence correctness, spectral characteristics of fluorescent dyes, activity and purity of DNA polymerase, concentration and purity of dNTPs, and accuracy of internal standard fragment length, etc. Each batch of raw materials must undergo incoming inspection, and a list of qualified suppliers must be established. During production, the preparation of the multiplex PCR premix must be performed in a clean environment to avoid cross-contamination, and the concentration uniformity of each component should be monitored through intermediate product testing. After aliquoting, the kit needs to undergo seal integrity checks to prevent leakage during transportation.

Finished product release testing should cover all key quality attributes, typically including: using standard reference materials to test the specificity and sensitivity of the kit; conducting repeatability validation on at least three independent batches of the kit; and performing accelerated stability testing (such as storage at 37°C for one week) to evaluate short-term transportation tolerance. In addition, the kit's labels, instructions, and packaging integrity also need to be verified. For products involving fluorescent labeling, it is recommended to perform batch-to-batch comparison of the fluorescence signal intensity and background noise of each kit batch to ensure consistency in instrument reading. Production records and inspection records should be complete and traceable, complying with the requirements of medical device quality management systems (such as ISO 13485).

Medical Device Registration and Regulatory Requirements

In China, the chromosome (13/18/21/X/Y) multiplex STR genotyping kit, as an in vitro diagnostic reagent, is usually registered and managed as a Class III medical device. Before registration application, enterprises need to complete the preparation of product technical requirements, analytical performance evaluation, clinical evaluation (or clinical trials), stability studies, etc. Among these, analytical performance evaluation should cover the aforementioned key quality attributes and include testing of extreme samples (such as highly hemolyzed and high bilirubin samples). For clinical evaluation, the same-variety comparison pathway may be chosen, or clinical trials may be conducted; clinical trials need to be designed in accordance with the Guiding Principles for Clinical Trials of In Vitro Diagnostic Reagents, selecting a representative target population, and using chromosome karyotype analysis or microarray analysis as the reference standard to evaluate the positive coincidence rate and negative coincidence rate of the kit.

The registration application materials also need to submit product instructions, risk management reports (according to YY/T 0316 risk analysis), production process flow charts and key process validation, production quality management system documents, etc. The Center for Medical Device Evaluation of the National Medical Products Administration will conduct a comprehensive review of product safety, effectiveness, and quality controllability. After obtaining the registration certificate, enterprises also need to continuously fulfill obligations such as post-market adverse event monitoring, product change registration, and annual quality control reports. Manufacturing enterprises should establish a medical device quality management system covering the entire process of design and development, procurement, production, inspection, sales, and after-sales service, and pass system assessment. For products planned for export, attention should also be paid to the corresponding regulatory requirements and performance standards of the target markets (such as EU IVDR and U.S. FDA).